Literature DB >> 33396289

Histological Correlation for Radiofrequency and Microwave Ablation in the Local Control of Hepatocellular Carcinoma (HCC) before Liver Transplantation: A Comprehensive Review.

Peiman Habibollahi1, Rahul A Sheth1, Erik N K Cressman1.   

Abstract

Radiofrequency ablation (RFA) and microwave ablation (MWA) are the most widely studied and applied ablation techniques for treating primary and secondary liver tumors. These techniques are considered curative for small hepatic tumors, with post-ablation outcomes most commonly assessed by an imaging follow up. However, there is increasing evidence of a discrepancy between radiological and pathological findings when ablated lesions are evaluated following liver resection or liver transplantation. A comprehensive review of the available literature reporting the complete pathological response (cPR) following RFA and MWA was performed to estimate the success rate and identify the factors associated with treatment failure. Following RFA, cPR is reported in 26-96% of tumors compared to 57-95% with MWA. Larger tumor size and vessels larger than 3 mm adjacent to the treated tumor are the most important factors identified by previous studies associated with viable residual tumors after RFA. Correlating post-ablation radiological studies with pathological findings shows that computed tomography (CT) and magnetic resonance imaging (MRI) have low sensitivity but high specificity for detecting residual viable or recurrent hepatocellular carcinoma (HCC) tumors. There are promising recent reports combining multiprobe ablation techniques with three-dimensional treatment planning software and stereotactic-aiming instrumentation to achieve more than 90% cPR in both small and large HCC tumors. In conclusion, the reported success for achieving cPR in HCC following RFA and MWA is highly variable in different studies and decreases with increasing lesion size and unfavorable tumor characteristics. Very few studies have reported a high rate of cPR. As these studies are single-center and retrospective, they need to be further validated and reproduced in other clinical settings.

Entities:  

Keywords:  hepatocellular carcinoma; histopathology; microwave ablation; radiofrequency ablation; thermal ablation

Year:  2020        PMID: 33396289     DOI: 10.3390/cancers13010104

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  6 in total

1.  Combined screening analysis of aberrantly methylated-differentially expressed genes and pathways in hepatocellular carcinoma.

Authors:  Jisen Cao; Ruiqiang Zhang; Ye Zhang; Yijun Wang
Journal:  J Gastrointest Oncol       Date:  2022-02

2.  Curative Analysis of Patients with Hepatocellular Carcinoma Using Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation.

Authors:  Yifan Li; Diwen Zhu; Weixin Ren; Junpeng Gu; Weizheng Ji; Haixiao Zhang; Yingjun Bao; Gengfei Cao; Asihaer Hasimu
Journal:  Med Sci Monit       Date:  2022-05-21

3.  Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma.

Authors:  Zhitao Chen; Tielong Wang; Chuanbao Chen; Xitao Hong; Jia Yu; Yihao Ma; Yiwen Guo; Changjun Huang; Xiaoshun He; Weiqiang Ju; Maogen Chen
Journal:  J Oncol       Date:  2021-10-19       Impact factor: 4.375

4.  Liver stiffness measured by magnetic resonance elastography in early recurrence of hepatocellular carcinoma after treatment: A protocol for systematic review and meta analysis.

Authors:  Huiyan Zhao; Lijun Zhang; Huadong Chen
Journal:  Medicine (Baltimore)       Date:  2021-06-11       Impact factor: 1.817

5.  Hyperthermia-Based Anti-Cancer Treatments.

Authors:  Johannes Crezee; Nicolaas A P Franken; Arlene L Oei
Journal:  Cancers (Basel)       Date:  2021-03-12       Impact factor: 6.639

6.  A Real-World Comparative Study of Microwave and Radiofrequency Ablation in Treatment-Naïve and Recurrent Hepatocellular Carcinoma.

Authors:  Soon Kyu Lee; Dong Jin Chung; Se Hyun Cho
Journal:  J Clin Med       Date:  2022-01-07       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.